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Edited by Ned ManteiAbstract Fractalkine (FKN) evokes nociceptive behavior in
naı¨ve rats, whereas minocycline attenuates pain acutely after
neuronal injury. We show that, in naı¨ve rats, FKN causes hyper-
responsiveness of lumbar wide dynamic range neurons to brush,
pressure and pinch applied to the hindpaw. One day after spinal
nerve ligation (SNL), minocycline attenuates after-discharge and
responses to brush and pressure. In contrast, minocycline does
not alter evoked neuronal responses 10 days after SNL or sciatic
constriction, but increases spontaneous discharge. We speculate
that microglia rapidly alter sensory neuronal activity in naı¨ve
and neuropathic rats acutely, but not chronically, after injury.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Evidence has recently emerged demonstrating the contribu-
tion of glia (mainly astrocytes and microglia) to neuropathic
pain [7,22,30,32–34] and attenuation of opioid analgesia
[6,17]. Nevertheless, the essential link tying microglial function
to neuronal processing of nociceptive information is missing.
Fractalkine (FKN) and minocycline are known modulators
of microglial function. Fractalkine is the only CX3C ligand-1
chemokine belonging to the CX3C family [28]. Intrathecal
administration of FKN evokes dose-dependent mechanical
allodynia and thermal hyperalgesia in naı¨ve rats [24], whereas
FKN-induced pain behavior is reversed by minocycline, an
inhibitor of microglia [25]. According to many in vivo and
in vitro studies, minocycline inhibits microglial activation un-
der various pathological conditions without aﬀecting neurons,
astroglia, or oligodendroglial progenitors [26,27]. In the spinal
cord, FKN receptor (CX3CR1) expression is up-regulated
after chronic constriction injury (CCI) of the sciatic nerve con-
comitantly with microglial activation [31]. Intrathecal adminis-
tration of a neutralizing antibody against CX3CR1 delays or
reduces neuropathic behavior [24]. In contrast, intrathecal
minocycline attenuates neuropathic behavior one day, but
not one week, following neuropathic injury [20].*Corresponding author. Fax: +1 401 444 8052.
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doi:10.1016/j.febslet.2006.06.087Accordingly, we hypothesized that FKN induces neuronal
hyperresponsiveness to natural stimuli in naı¨ve rats, whereas
minocycline reverses these aberrant changes in rats acutely,
but not chronically, after peripheral neuropathic injury.2. Materials and methods
Adult male Sprague-Dawley rats (200–250 g) were used. For spinal
nerve ligation (SNL), rats were anesthetized with isoﬂurane (1.5%)
and lumbar 5–6 spinal nerves tightly ligated with 6–0 silk thread
[19]. A slightly modiﬁed CCI was induced by placing three (instead
of four) loose chromic gut (4–0) ligatures around the sciatic nerve
[1]. Mechanical and thermal nociceptive thresholds were determined
as previously described [2,8,9].
Rats were anesthetized with sodium pentobarbital (i.e., 60 mg/kg)
for extracellular single unit recording using Spike2. Neuronal units
were isolated based on their responses to natural stimuli within recep-
tive ﬁelds strictly mapped on the ipsitaleral hindpaw (only units at
depth <250 lm corresponding to laminae I–II were studied). Five
mechanical stimuli were applied in the following order: Brush, by a
cotton applicator to the skin; 3 von Frey ﬁlaments of non-nociceptive
(0.6 g) and nociceptive (8 and 15 g) strengths, respectively; pressure or
pinch by attaching arterial clip (144 or 583 g/mm2). Only multirecep-
tive wide dynamic range (WDR) neurons were selected. Background
discharge was recorded for 20 s, and stimuli were applied serially for
20 s. Receptive ﬁelds were clearly marked by coloring the dermatome
to monitor changes in size that could be caused by drug or vehicle
application. Activities of 2–3 U/rat were recorded from 3 to 4 rats/
group (6–12 U/group).
A cotton pledget soaked with FKN solution (30 ng in 10 ll aCSF,
R&D systems) or vehicle was placed on the spinal cord proximal to
the site of electrode penetration. Activity was recorded from single
units 10–20 min before or 20–50 min following FKN or vehicle appli-
cation. Similarly, minocycline hydrochloride (Sigma) or vehicle was
applied to the spinal cord (100 lg in 10 ll aCSF). Signiﬁcance was
computed using Student’s t-test and Fisher’s exact test.3. Results
Repetitive natural stimulation and application of vehicle did
not aﬀect spontaneous or evoked neuronal activity. Behavioral
testing of rats with peripheral nerve injury on the same day
prior to recording conﬁrmed decreases in mechanical and ther-
mal thresholds associated with neuropathic pain (Fig. 1).
In naı¨ve rats, neuronal activity increased after FKN applica-
tion in all units. In particular, mean responses to brush,
pressure and pinch were signiﬁcantly (P < 0.05) increased from
6 ± 0.8, 7.4 ± 3.0 and 10.6 ± 2.1 to 16.4 ± 3.5, 15.5 ± 4.3
and 20 ± 3.4, respectively (Fig. 2A, n = 11 U/group, mean
responses to other stimuli were not signiﬁcantly diﬀerent). In
contrast, minocycline did not change neuronal activity in naı¨ve
rats (Fig. 2B, n = 6–11 U/group).blished by Elsevier B.V. All rights reserved.
Fig. 1. Mechanical thresholds and thermal withdrawal latencies are
shown for hindpaws ipsilateral and contralateral to injury by SNL or
CCI (n = 5 rats/group, ±S.E.M, dotted line represents baseline values).
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was observed after minocycline application in all units re-
corded. Particularly, mean responses to brush and pressureFig. 2. Traces in left panels illustrate neuronal activity in naı¨ve rats before a
show baseline activity before drug application; lower traces show activity of
in A show signiﬁcant (*P < 0.05) increases in the mean responses to brush (BR
FKN. No change was observed after minocycline (B).stimuli were signiﬁcantly (P < 0.05) decreased from 10.6 ±
3.1 and 9.4 ± 2.1 to 4.6 ± 1.4 and 5.1 ± 2.1, respectively
(Fig. 3A, n = 9–10 U/group, mean responses to other stimuli
were not signiﬁcantly diﬀerent).
In rats 10 days after SNL, no change in evoked responses
was observed in any unit after minocycline application
(n = 8–9 U/group, data not shown). However, an increase in
spontaneous discharge emerged during periods of un-evoked
activity from 2.4 ± 0.6 to 5.7 ± 2.1 (Fig. 3B, n = 8–9 U/group).
To further corroborate these results, neuronal activity was sim-
ilarly recorded in rats (n = 4) 10 days after CCI; in these rats,
spontaneous discharge increased from 2.1 ± 1.3 to 4 ± 0.8 fol-
lowing minocycline (Fig. 3B, n = 9–10 U/group), whereas
evoked responses were not changed.
Generally, neuronal modulation by FKN or minocycline
reached maximal levels within 30 min (Fig. 4), with a tendency
for reversal 50 min following minocycline in rats one day after
SNL (Fig. 4A). In naı¨ve rats, however, hyperresponsiveness
remained elevated 50 min after FKN application (Fig. 4A
and B).
After-discharge observed following noxious pinch stimuli
(deﬁned as continuous discharge after stimulus removal) was
studied in all units (Fig. 5). In naı¨ve rats, FKN increased the
number of units exhibiting after-discharge from 12.5% to
72.7% (n = 8–11 U/group, P < 0.05). In rats one day after
SNL, after-discharge was only observed in 11.1% of units after
minocycline application compared to 50.0% (n = 9–10 U/
group, P < 0.05); ten days after SNL, however, no signiﬁcant
change was observed after minocycline (75.0% compared tond 20 min after FKN (A) or minocycline (B). Upper traces in A and B
the same unit respectively 20 min after drug application. Right panels
), pressure (PR) and pinch (PI) of units recorded before (naı¨ve) or after
Fig. 3. Panels in A were constructed similarly to those in Fig. 2; note signiﬁcant decreases (*P < 0.05) in mean responses to brush and pressure
stimuli after minocycline application in rats d1 after SNL. However, signiﬁcant (*P < 0.05) increase in spontaneous activity (bk, 20 s preceding BR
stimulus) was evident when mean values were computed at d10 after SNL (B example from one unit is shown in right panel). Similar results were
found for rats 10 days after CCI.
Fig. 4. Time course of neuronal modulation by FKN or minocycline
was computed in 3 U/group as percent change in brush-evoked
responses compared to baseline at 10, 30 and 50 min after drug
application (A); example from one unit in B shows percent increases in
brush and pinch-evoked responses after FKN.
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mained constant for each unit recorded before and after
FKN or minocycline application.4. Discussion
In this study, we tested our hypothesis that activity of WDR
neurons in the superﬁcial dorsal horn of the spinal cord is al-
tered by FKN or minocycline known to inﬂuence sensory
behavior and to activate or inhibit microglia, respectively.
Fractalkine caused neuronal hyperresponsiveness to brush,
pressure and noxious pinch in naı¨ve rats, in addition to an in-
crease in the number of cells with after-discharge typically
associated with spontaneous pain behavior and ‘wind-up’
[23]. These results are in agreement with neuropathic behavior
following intrathecal administration of FKN at a similar con-
centration [24]. In rats with peripheral nerve injury, reversal of
aberrant neuronal responses with minocycline one day, but not
ten days after SNL (except for an increase in spontaneous dis-
charge), strongly supports behavioral data describing attenua-
tion of neuropathic pain using minocycline at a similar
concentration acutely, but not chronically following neuronal
injury [13,20]. Furthermore, the increased spontaneous activity
observed in this study following minocycline indicates a poten-
tial neuroprotective role for microglia chronically after injury,
regardless of injury incongruity by SNL or CCI. Interestingly,
nociceptive behavior in rodents is usually tested based on with-
drawal reﬂexes evoked in response to natural stimuli, while
spontaneous pain behavior is generally overlooked.
Although our results suggest that FKN may cause neuronal
sensitization (hyperresponsiveness and burst ﬁring, data not
shown), it does not however enlarge the receptive ﬁeld area,
a phenomenon often associated with central sensitization. In
addition, minocycline did not reduce receptive ﬁeld sizes in
rats with peripheral nerve injury, suggesting that FKN and
minocycline do not fully contribute to sensitization of WDR
neurons. Our ﬁndings are inconsistent, however, with the
Fig. 5. Bar histograms show percent number of units with after-discharge in each group (*P < 0.05). One example (right panel) shows action
potentials (upper traces) in a rat d1 after SNL derived from corresponding rate histograms (lower traces) of the same unit with maintained discharge
after stimulus removal (arrow, pinch applied within period indicated by dashed vertical lines); note absence of after-discharge activity 20 min
following minocycline application.
S.A. Owolabi, C.Y. Saab / FEBS Letters 580 (2006) 4306–4310 4309attenuation of tactile allodynia ten days after SNL by
spinal inhibition of p38-mitogen activated protein kinase
(p38MAPK) expressed in microglia, consequently inhibiting
microglia [16]. It should be noted that the anti-allodynic eﬀects
observed by Jin and colleagues [16] occurred 3 h following
microglial inhibition, whereas our analysis of neuronal activity
was mostly restricted to approximately 30 min following min-
ocycline application. Alternatively, our experimental design re-
quires the use of anesthetics, which have been reported to
inﬂuence glial function [21]. For more conclusive data interpre-
tation, recording neuronal activity in non-anesthetized animals
is recommended for future studies using chronically implanted
microelectrodes. Nonetheless, we speculate that microglia’s
contribution to pathological pain might diﬀer between the
acute or the chronic phase when astrocytes relay the pro-noci-
ceptive drive [26].
Many types of peripheral nerve injuries trigger nociceptive
behavior associated with microglial activation [5,10–12,14–
16,29]. Although little is known about signaling between
peripheral neurons and glia, Colburn et al. [3] speculated that
microglial activation depended on dorsal root mediated signals
(also refer to [4] identifying BDNF as a potent microglia-to-
neuron signal). For example, FKN in the spinal cord is consti-
tutively expressed by neurons and tethered to the membrane
surface of primary aﬀerents, whereas its receptor (CX3CR1)
is predominantly expressed by microglia [31]. Following
peripheral nerve injury, CX3CL1 is cleaved in the spinal cord
and couple to CX3CR1, thus activating microglia [34,35].
Upon activation, microglia secrete proinﬂammatory mediators
such as prostaglandins, proteases, cytokines (TNF-a, IL-1b,
IL-6) and excitatory amino acids [18] whose receptors are ex-
pressed on dorsal horn neurons. In addition, microglia gener-
ate reactive oxygen species and nitrogen intermediates of
adverse consequences regarding neuronal physiology.
In light of these observations, attenuation of neuronal sensi-
tization by minocycline could be interpreted as resulting from
a transient interruption in microglial release of proinﬂamma-
tory mediators. We therefore conclude that the modulation
of neuropathic behavior induced by FKN or minocycline
may be explained in part by microglia-to-neuron signaling in
the spinal cord dorsal horn.
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